Fayez Sarofim & Co’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.2M Sell
51,857
-438
-0.8% -$156K 0.05% 79
2025
Q4
$17.1M Buy
52,295
+490
+0.9% +$155K 0.04% 90
2025
Q3
$14.6M Sell
51,805
-341
-0.7% -$98.9K 0.03% 95
2025
Q2
$14.6M Buy
52,146
+18,213
+54% +$5.16M 0.03% 97
2025
Q1
$10.6M Buy
33,933
+1,116
+3% +$330K 0.03% 101
2024
Q4
$8.55M Buy
32,817
+8,215
+33% +$2.44M 0.02% 106
2024
Q3
$7.93M Buy
24,602
+440
+2% +$144K 0.02% 107
2024
Q2
$7.55M Sell
24,162
-637
-3% -$187K 0.02% 106
2024
Q1
$7.05M Sell
24,799
-171
-0.7% -$50K 0.02% 106
2023
Q4
$7.27M Sell
24,970
-804
-3% -$219K 0.02% 102
2023
Q3
$6.93M Sell
25,774
-550
-2% -$137K 0.02% 100
2023
Q2
$5.84M Buy
26,324
+24
+0.1% +$5.57K 0.02% 99
2023
Q1
$6.36M Buy
26,300
+1,661
+7% +$408K 0.02% 99
2022
Q4
$6.47M Sell
24,639
-75
-0.3% -$20.1K 0.02% 100
2022
Q3
$5.57M Buy
24,714
+126
+0.5% +$30.5K 0.02% 107
2022
Q2
$5.98M Sell
24,588
-1,238
-5% -$303K 0.02% 111
2022
Q1
$6.25M Buy
25,826
+1,954
+8% +$449K 0.02% 114
2021
Q4
$5.37M Buy
23,872
+9,204
+63% +$1.94M 0.02% 119
2021
Q3
$3.12M Sell
14,668
-4,127
-22% -$950K 0.01% 133
2021
Q2
$4.58M Sell
18,795
-1,334
-7% -$328K 0.02% 124
2021
Q1
$5.01M Sell
20,129
-11,720
-37% -$2.8M 0.02% 105
2020
Q4
$7.32M Buy
31,849
+1,213
+4% +$280K 0.03% 95
2020
Q3
$7.79M Sell
30,636
-97
-0.3% -$24K 0.03% 90
2020
Q2
$7.25M Buy
30,733
+5,299
+21% +$1.21M 0.03% 92
2020
Q1
$5.16M Buy
25,434
+350
+1% +$76.4K 0.03% 94
2019
Q4
$6.05M Buy
25,084
+1,023
+4% +$226K 0.03% 103
2019
Q3
$4.66M Sell
24,061
-108
-0.4% -$20.7K 0.02% 104
2019
Q2
$4.45M Sell
24,169
-27
-0.1% -$4.83K 0.02% 108
2019
Q1
$4.6M Sell
24,196
-4,213
-15% -$805K 0.02% 111
2018
Q4
$5.53M Buy
28,409
+463
+2% +$90.3K 0.03% 100
2018
Q3
$5.79M Hold
27,946
0.03% 104
2018
Q2
$5.16M Sell
27,946
-2,426
-8% -$429K 0.03% 105
2018
Q1
$5.18M Sell
30,372
-180
-0.6% -$33K 0.03% 104
2017
Q4
$5.31M Sell
30,552
-4,513
-13% -$799K 0.03% 101
2017
Q3
$6.54M Hold
35,065
0.03% 97
2017
Q2
$6.04M Hold
35,065
0.03% 101
2017
Q1
$5.75M Sell
35,065
-26,305
-43% -$4.37M 0.03% 103
2016
Q4
$8.97M Buy
61,370
+26,779
+77% +$4.03M 0.05% 94
2016
Q3
$5.77M Sell
34,591
-100
-0.3% -$16.9K 0.03% 108
2016
Q2
$5.28M Sell
34,691
-2,784
-7% -$433K 0.03% 108
2016
Q1
$5.62M Buy
37,475
+26,728
+249% +$3.97M 0.03% 102
2015
Q4
$1.75M Buy
10,747
+126
+1% +$19.8K 0.01% 129
2015
Q3
$1.47M Hold
10,621
0.01% 130
2015
Q2
$1.63M Hold
10,621
0.01% 124
2015
Q1
$1.7M Hold
10,621
0.01% 126
2014
Q4
$1.69M Buy
10,621
+4,920
+86% +$767K 0.01% 129
2014
Q3
$801K Hold
5,701
﹤0.01% 157
2014
Q2
$675K Buy
5,701
+220
+4% +$25.5K ﹤0.01% 170
2014
Q1
$676K Sell
5,481
-125
-2% -$15.2K ﹤0.01% 166
2013
Q4
$640K Buy
+5,606
New +$638K ﹤0.01% 169
2013
Q2
$543K Buy
+5,507
New +$571K ﹤0.01% 168

Other funds holding AMGN

Fayez Sarofim & Co's AMGN Position: Q1 2026 in Review

Fayez Sarofim & Co reduced its Amgen (AMGN) stake by 0.84% in Q1 2026, selling an estimated $156K and leaving 51,857 shares worth $18.2M. The position accounts for 0.05% of the portfolio, ranked #79.

Fayez Sarofim & Co first reported a position in AMGN in Q2 2013 and has held it in 51 quarters since. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Fayez Sarofim & Co held 51,857 shares of Amgen worth $18.2M as of Q1 2026.
  • Fayez Sarofim & Co sold 438 Amgen shares in Q1 2026, an estimated $156K.
  • Amgen made up 0.05% of Fayez Sarofim & Co's portfolio in Q1 2026, its #79 holding.
  • Fayez Sarofim & Co first reported a position in Amgen in Q2 2013 and has held it in 51 quarters since.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.